|
1
|
Huang S, Zou X, Zhu JN, Fu YH, Lin QX,
Liang YY, Deng CY, Kuang SJ, Zhang MZ, Liao YL, et al: Attenuation
of microrna-16 derepresses the cyclins d1, d2 and e1 to provoke
cardiomyocyte hypertrophy. J Cell Mol Med. 19:608–619. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chien KR, Shimizu M, Hoshijima M,
Minamisawa S and Grace AA: Toward molecular strategies for heart
disease-past, present, future. Jpn Circ J. 61:91–118. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tao L, Bei Y, Chen P, Lei Z, Fu S, Zhang
H, Xu J, Che L, Chen X, Sluijter JP, et al: Crucial role of mir-433
in regulating cardiac fibrosis. Theranostics. 6:2068–2083. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thannickal VJ, Zhou Y, Gaggar A and Duncan
SR: Fibrosis: Ultimate and proximate causes. J Clin Invest.
124:4673–4677. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thum T and Lorenzen JM: Cardiac fibrosis
revisited by microRNA therapeutics. Circulation. 126:800–802. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olson EN: Micrornas as therapeutic targets
and biomarkers of cardiovascular disease. Sci Transl Med.
6:239ps32014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X, Wu D, Du H, Nie F, Pang X and Xu
Y: MicroRNA-135a is involved in podocyte injury in a transient
receptor potential channel 1-dependent manner. Int J Mol Med.
40:1511–1519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou B, Li H and Shi J: miR-27 inhibits
the NF-κB signaling pathway by targetingleptin in osteoarthritic
chondrocytes. Int J Mol Med. 40:523–530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thum T: Noncoding RNAs and myocardial
fibrosis. Nat Rev Cardiol. 11:655–663. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tao H, Yang JJ and Shi KH: Non-coding RNAs
as direct and indirect modulators of epigenetic mechanism
regulation of cardiac fibrosis. Expert Opin Ther Targets.
19:707–716. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumarswamy R and Thum T: Non-coding RNAs
in cardiac remodeling and heart failure. Circ Res. 113:676–689.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Espinoza-Lewis RA: Wang DZ. MicroRNAs in
heart development. Curr Top Dev Biol. 100:279–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Small EM and Olson EN: Pervasive roles of
microRNAs in cardiovascular biology. Nature. 469:336–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi J, Wang L, Lu Y, Ji Y, Wang Y, Dong K,
Kong X and Sun W: Protective effects of seabuckthorn pulp and seed
oils against radiation-induced acute intestinal injury. J Radiat
Res. 58:24–32. 2017. View Article : Google Scholar :
|
|
15
|
Bourajjaj M, Armand AS, da Costa Martins
PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XH and De Windt
LJ: Nfatc2 is a necessary mediator of calcineurin-dependent cardiac
hypertrophy and heart failure. J Biol Chem. 283:22295–22303. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Y, Zhu X, Li J, Fang R, Wang Z, Zhang
J, Li K, Li X, Bai H, Yang Q, et al: Glycine prevents pressure
overload induced cardiac hypertrophy mediated by glycine receptor.
Biochem Pharmacol. 123:40–51. 2017. View Article : Google Scholar
|
|
17
|
Zaid TM, Yeung TL, Thompson MS, Leung CS,
Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C,
Lopez-Berestein G, et al: Identification of FGFR4 as a potential
therapeutic target for advanced-stage, high-grade serous ovarian
cancer. Clin Cancer Res. 19:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng Y, Zhu Y, Zhang J, Duan X and Zhang
Y: Large accumulation of collagen and increased activation of mast
cells in hearts of mice with hyperlipidemia. Arq Bras Cardiol.
109:404–409. 2017.In English, Portuguese. PubMed/NCBI
|
|
19
|
Irelan JT, Wu MJ, Morgan J, Ke N, Xi B,
Wang X, Xu X and Abassi YA: Rapid and quantitative assessment of
cell quality, identity, and functionality for cell-based assays
using real-time cellular analysis. J Biomol Screen. 16:313–322.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xing D and Orsulic S: A genetically
defined mouse ovarian carcinoma model for the molecular
characterization of pathway-targeted therapy and tumor resistance.
Proc Natl Acad Sci USA. 102:6936–6941. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔC T method. Methods. 25:402–408.
2001. View Article : Google Scholar
|
|
22
|
Heineke J and Molkentin JD: Regulation of
cardiac hypertrophy by intracellular signalling pathways. Nat Rev
Mol Cell Biol. 7:589–600. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maillet M, van Berlo JH and Molkentin JD:
Molecular basis of physiological heart growth: Fundamental concepts
and new players. Nat Rev Mol Cell Biol. 14:38–48. 2013. View Article : Google Scholar
|
|
24
|
Dirkx E, Gladka MM, Philippen LE, Armand
AS, Kinet V, Leptidis S, El Azzouzi H, Salic K, Bourajjaj M, da
Silva GJ, et al: Nfat and mir-25 cooperate to reactivate the
transcription factor hand2 in heart failure. Nat Cell Biol.
15:1282–1293. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Melman YF, Shah R and Das S: Micrornas in
heart failure: Is the picture becoming less mirky. Circ Heart Fail.
7:203–214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roncarati R, Viviani Anselmi C, Losi MA,
Papa L, Cavarretta E, Da Costa Martins P, Contaldi C, Saccani Jotti
G, Franzone A, Galastri L, et al: Circulating miR-29a, among other
up-regulated microRNAs, is the only biomarker for both hypertrophy
and fibrosis in patients with hypertrophic cardiomyopathy. J Am
Coll Cardiol. 63:920–927. 2014. View Article : Google Scholar
|
|
27
|
Wang J, Liew OW, Richards AM and Chen YT:
Overview of MicroRNAs in cardiac hypertrophy, fibrosis, and
apoptosis. Int J Mol Sci. 17:pii: E7492016. View Article : Google Scholar
|
|
28
|
Wu C, Dong S and Li Y: Effects of
miRNA-455 on cardiac hypertrophy induced by pressure overload. Int
J Mol Med. 35:893–900. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ling H, Fabbri M and Calin GA: Micrornas
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gacoń J, Kabłak-Ziembicka A, Stępień E,
Enguita FJ, Karch I, Derlaga B, Żmudka K and Przewłocki T:
Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in
patients with occluded target vessel in acute coronary syndrome.
Kardiol Pol. 74:280–288. 2016. View Article : Google Scholar
|
|
31
|
Gao H, Guddeti RR, Matsuzawa Y, Liu LP, Su
LX, Guo D, Nie SP, Du J and Zhang M: Plasma levels of microRNA-145
are associated with severity of coronary artery disease. PLoS One.
10:e01234772015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao W, He HW, Wang ZM, Zhao H, Lian XQ,
Wang YS, Zhu J, Yan JJ, Zhang DG, Yang ZJ and Wang LS: Plasma
levels of lipometabolism-related miR-122 and mir-370 are increased
in patients with hyperlipidemia and associated with coronary artery
disease. Lipids Health Dis. 11:552012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang F, Long G, Zhao C, Li H, Chaugai S,
Wang Y, Chen C and Wang DW: Plasma microRNA-133a is a new marker
for both acute myocardial infarction and underlying coronary artery
stenosis. J Transl Med. 11:2222013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thum T, Gross C, Fiedler J, Fischer T,
Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et
al: MicroRNA-21 contributes to myocardial disease by stimulating
map kinase signalling in fibroblasts. Nature. 456:980–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Huang W, Xu R, Nie Y, Cao X, Meng
J, Xu X, Hu S and Zheng Z: MicroRNA-24 regulates cardiac fibrosis
after myocardial infarction. J Cell Mol Med. 16:2150–2160. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ye Y, Perez-Polo JR, Qian J and Birnbaum
Y: The role of microRNA in modulating myocardial
ischemia-reperfusion injury. Physiol Genomics. 43:534–542. 2011.
View Article : Google Scholar
|
|
37
|
Dong S, Cheng Y, Yang J, Li J, Liu X, Wang
X, Wang D, Krall TJ, Delphin ES and Zhang C: MicroRNA expression
signature and the role of microRNA-21 in the early phase of acute
myocardial infarction. J Biol Chem. 284:29514–29525. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kong P, Christia P and Frangogiannis NG:
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci.
71:549–574. 2014. View Article : Google Scholar
|
|
39
|
Gyöngyösi M, Winkler J, Ramos I, Do QT,
Firat H, McDonald K, González A, Thum T, Diez J, Jaisser F, et al:
Myocardial fibrosis: Biomedical research from bench to bedside. Eur
J Heart Fail. 19:177–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weber KT, Sun Y, Bhattacharya SK, Ahokas
RA and Gerling IC: Myofibroblast-mediated mechanisms of
pathological remodelling of the heart. Nat Rev Cardiol. 10:15–26.
2013. View Article : Google Scholar
|
|
41
|
Esposito G, Perrino C, Schiattarella GG,
Belardo L, di Pietro E, Franzone A, Capretti G, Gargiulo G, Pironti
G, Cannavo A, et al: Induction of mitogen-activated protein kinases
is proportional to the amount of pressure overload. Hypertension.
55:137–143. 2010. View Article : Google Scholar
|
|
42
|
Haq S, Choukroun G, Lim H, Tymitz KM, del
Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T and
Molkentin JD: Differential activation of signal transduction
pathways in human hearts with hypertrophy versus advanced heart
failure. Circulation. 103:670–677. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Peterson KL: Pressure overload hypertrophy
and congestive heart failure. Where is the 'Achilles' heel'. J Am
Coll Cardiol. 39:672–675. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rose BA, Force T and Wang Y:
Mitogen-activated protein kinase signaling in the heart: Angels
versus demons in a heart-breaking tale. Physiol Rev. 90:1507–1546.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie
K, Li J, Liu R, Zhang T, Xie N, et al: Proteomics identification of
ITGB3 as a key regulator in reactive oxygen species-induced
migration and invasion of colorectal cancer cells. Mol Cell
Proteomics. 10:M110 0053972011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miller PG, Al-Shahrour F, Hartwell KA, Chu
LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey
ME, et al: In vivo RNAi screening identifies a leukemia-specific
dependence on integrin beta 3 signaling. Cancer Cell. 24:45–58.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mazalouskas M, Jessen T, Varney S,
Sutcliffe JS, Veenstra-VanderWeele J, Cook EH Jr and Carneiro AM:
Integrin β3 haploinsufficiency modulates serotonin transport and
antidepressant-sensitive behavior in mice. Neuropsychopharmacology.
40:2015–2024. 2015. View Article : Google Scholar : PubMed/NCBI
|
